OncoC4 Reports Encouraging Phase 1/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026

The Quick Take
— 33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with PD-(L)1-resistant/refractory NSCLC — — Preliminary efficacy and safety results support further development of cesalatamig monotherapy — ROCKVILLE, Md., Nov. 6,...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Local
The Cannabis Industry Came Together To Stop A Rollback In Massachusetts, But We Must Remain United For The Next Fight (Op-Ed)
“For too long, cannabis businesses, advocates, veterans, patients and policymakers have operated in separate corners of the same fight. We have allowed…
Business
Tetragon Financial Group Limited Dividend Information in Respect of Q3 2026
LONDON, Nov. 6, 2026 /PRNewswire/ -- On 27 October 2026, the Board of Directors of Tetragon declared a dividend of U.S.$0.12 (12.00 cents) per share in respect…
Business
Brian Long of Atlantic Bridge announces departure to form own technology investment fund
DUBLIN, Nov. 6, 2026 /PRNewswire/ -- Brian Long, co-founder and Managing Partner of Atlantic Bridge, is leaving Atlantic Bridge, a leading growth equity firm…
Business
Smart Greenhouse Market worth $4.13 billion by 2032 - Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., Nov. 6, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Smart Greenhouse Market is estimated at USD 2.18 billion in 2026 and USD…
